Holen Sie sich die Stockscreener-App
0.8661
20.17%
0.1454
Handel nachbörslich:
.87
0.0039
+0.45%
Schlusskurs vom Vortag:
$0.7207
Offen:
$0.734
24-Stunden-Volumen:
4.73M
Relative Volume:
2.02
Marktkapitalisierung:
$140.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-111.13M
KGV:
-0.6561
EPS:
-1.32
Netto-Cashflow:
$-91.53M
1W Leistung:
+25.92%
1M Leistung:
+50.89%
6M Leistung:
-38.14%
1J Leistung:
-76.21%
1-Tages-Spanne:
$0.734
$0.87
1-Wochen-Bereich:
$0.666
$0.87
52-Wochen-Spanne:
$0.36
$4.06
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Firmenname
Tenaya Therapeutics Inc
Sektor
Branche
Telefon
415-865-2066
Adresse
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Vergleichen Sie TNYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.8661 | 111.88M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-10 | Eingeleitet | William Blair | Outperform |
| 2023-11-30 | Eingeleitet | Leerink Partners | Outperform |
| 2022-06-15 | Eingeleitet | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
Why Tenaya Therapeutics Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser
What makes Tenaya Therapeutics Inc. stock price move sharplyFree Best Performing Stock Suggestions - Newser
58,547 Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Bought by Wealth Enhancement Advisory Services LLC - Defense World
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 0.3% – Here’s Why - Defense World
Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $6.25 - Defense World
Millennium Management LLC Sells 174,447 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) and Alpha Cognition (NASDAQ:ACOG) Critical Survey - Defense World
Squarepoint Ops LLC Decreases Stock Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Nuveen Asset Management LLC Buys 69,377 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Deutsche Bank AG Acquires 97,318 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Northern Trust Corp Grows Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics Appoints New Directors at Annual Meeting - TipRanks
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average Target Price from Brokerages - Defense World
Price T Rowe Associates Inc. MD Sells 2,892,201 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics chief medical officer sells $1,300 in stock By Investing.com - Investing.com Nigeria
Tenaya therapeutics SVP Higa Tomohiro sells $615 in stock By Investing.com - Investing.com India
Tenaya Therapeutics chief medical officer sells $1,300 in stock - Investing.com Australia
Tenaya therapeutics SVP Higa Tomohiro sells $615 in stock - Investing.com
Tenaya Therapeutics Awards Major Stock Options Package: 461K Shares for Strategic New Hires - Stock Titan
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Greenlane Renewables Announces First Quarter 2025 Financial Results - The Globe and Mail
Barclays PLC Sells 184,837 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (TNYA) to Showcase Key Research at ASGCT 2025 | TNYA Stock News - GuruFocus
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting - The Manila Times
Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting - Nasdaq
Tenaya Therapeutics to Highlight Capsid Engineering, Gene - GlobeNewswire
Hsbc Holdings PLC Purchases New Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Equities Analysts Issue Forecasts for TNYA Q2 Earnings - Defense World
Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at Chardan Capital - Defense World
We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate - Yahoo Finance
Chardan Capital Maintains Buy Rating for Tenaya Therapeutics (TNYA) | TNYA Stock News - GuruFocus
Tenaya Therapeutics Reports Q1 2025 Financial Results - TipRanks
Tenaya (TNYA) Reports Promising Clinical Trial Developments and Financial Outlook | TNYA Stock News - GuruFocus
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
A Cautious Investment in the Drone Sector - The Globe and Mail
Geode Capital Management LLC Sells 27,419 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Why To Invest In Tenaya Therapeutics Inc (NASDAQ: TNYA) Stock? - Marketing Sentinel
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock - Investing.com Australia
TNYATenaya Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Tenaya reports progress in ARVC gene therapy study - Investing.com
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 - The Manila Times
Tenaya Therapeutics Presents Interim Data from RIDGE™ - GlobeNewswire
Major Breakthrough: 175-Patient ARVC Study Shows 93% Could Benefit from New Gene Therapy Treatment - Stock Titan
Strategy (MSTR) Buys Another $556 Million Worth of Bitcoin - The Globe and Mail
Finanzdaten der Tenaya Therapeutics Inc-Aktie (TNYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):